BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avalon Ventures Raises $201 Million Toward New VC Fund


8/31/2012 10:14:30 AM

Boston Business Journal by Kyle Alspach, VC Editor

Avalon Ventures, a Cambridge- and California-based venture capital firm whose portfolio includes Zynga (Nasdaq: ZNGA), has raised $201.6 million toward its 10th venture capital fund, according to a federal filing Thursday.

The firm wrote in the filing that it may raise up to $250 million in total for the new fund. Avalon has targeted $200 million for the fund, the same size as its current fund, with a cap at $250 million.

The successful fundraise for Avalon comes even as its most prominent investment, Zynga, continues to disappoint as a public company. Shares in the company currently stand at $2.89, down from the IPO price of $10 last December.

Zynga filings give no indication that Avalon has sold its stake in the company since the IPO, unlike VCs such as Union Square Ventures and Institutional Partners. That puts Avalon's shares at about $100 in value, compared to the $416 million they were worth after the IPO.

It remains a superb return for Avalon, however, which invested $4.5 million into Zynga in 2008 and sold shares worth $20.9 million prior to the IPO.

Other recent exits have included Amira Pharmaceuticals, BioVex Group, Cloudkick, Pictela and Ortiva Wireless, according to PE Hub.

Avalon's current portfolio includes a number of Boston area startups, including fast-growing tech firms Nanigans, Kinvey, Backupify and Cloudant.




 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES